Scinai Immunotherapeutics
SCNI
8 hedge funds and large institutions have $689K invested in Scinai Immunotherapeutics in 2017 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, reducing their positions, and 0 closing their positions.
320% more capital invested
Capital invested by funds: $164K → $689K (+$525K)
100% more funds holding
Funds holding: 4 → 8 (+4)
0.42% more ownership
Funds ownership: 0.15% → 0.57% (+0.42%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$222K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$213K |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
+$156K |
| 4 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
+$24.6K |
| 5 |
VIA
Vantage Investment Advisors
State College,
Pennsylvania
|
+$16.4K |
Top Sellers
SCNI Hedge Fund Activity: Q3 2017 in Review
8 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Scinai Immunotherapeutics (SCNI) for Q3 2017, worth a combined $689K — up 320% from $164K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new SCNI positions and 0 closed out — a net gain of 4 holders — while 2 added to existing stakes and 0 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $222K.
- 8 institutional investors held Scinai Immunotherapeutics (SCNI) as of Q3 2017, up from 4 in Q2 2017.
- Funds reported $689K of Scinai Immunotherapeutics stock for Q3 2017, up 320% quarter-over-quarter.
- 4 funds opened new Scinai Immunotherapeutics positions in Q3 2017 and 0 closed out, a net change of +4 holders.
- The largest Scinai Immunotherapeutics buyer in Q3 2017 was Renaissance Technologies, an estimated $222K added.
Based on aggregated 13F filings for Q3 2017.